EIF2A and metabolic dysfunction-associated steatotic liver disease: It has been reported that eIF2α could modulate transcription of several key molecules in other diseases, including abdominal aortic aneurysm (Ni et al., 2018), nonalcoholic fatty liver disease (Gao et al., 2016), and drug-induced liver dysfunction (Wang et al., 2016).